Genomma Lab posts 5.5% rise in Q2 2026 net income as gross margin expands 106 bps to 64.6%
AI Market Summary
Genomma Lab reported Q2 2026 results showing net income up 5.5% and gross margin expanding 106 bps to 64.6%, while like-for-like sales fell 3.6% amid softness in Mexico and the U.S. Hispanic market. Management noted early-July Mexico retail sellout turning positive, supported by product launches such as Suerox Mineral, and reiterated expectations for a gradual H2 recovery. The update is company-specific with limited cross-market spillover.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.09%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Genomma Lab Internacional (BMV: LAB B) reported second-quarter 2026 results with net income up 5.5% year over year and gross margin expanding 106 basis points to 64.6%. EBITDA margin was 21.8%, in line with the company’s expectations. Consolidated like-for-like sales fell 3.6%, though monitored retailer sellout in Mexico turned positive in the first two weeks of July, the company said.
